In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...

Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

KFDA approves Argenxs Vibgart for severe myasthenia gravis treatment KFDA greenlights innovative therapy for muscle weakness ...

Myasthenia gravis (MG) does not have stages but classes. These classes describe the muscles the condition affects and the severity of muscle weakness, which can influence the treatments a doctor ...

Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

USA-based healthcare giant Johnson & Johnson has announced the publication of key Phase III data for nipocalimab in The ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

Prescott Park Arts Festival's Sweetheart Deal is back PORTSMOUTH — Prescott Park Arts Festival has brought back their ...

TG Therapeutics is entering 2025 with investors accustomed to a beat-and-raise guidance policy and the company needs to ...